Local & Trade News | Jul 09, 2025

DKSH Singapore Receives Approval of Donanemab for the Treatment of Early Symptomatic Alzheimer’s Disease

Donanemab is the first amyloid plaque-targeting therapy approved in Singapore



Singapore, July 9, 2025 – DKSH Singapore is pleased to announce the approval of donanemab1 on March 11, 2025, in Singapore. Donanemab is the first amyloid plaque-targeting for Alzheimer’s disease approved in Singapore1. This landmark approval represents a significant advancement in the treatment landscape, marking a pivotal step forward in improving long-term outcomes to patients and caregivers. 

Donanemab is indicated to slow disease progression in adult patients with Alzheimer’s disease (AD). Treatment with donanemab should be initiated in patients with evidence of amyloid beta pathology and either mild cognitive impairment or mild dementia1. By actively reducing these plaques, donanemab has been shown to slow the disease progression and preserve cognitive and functional abilities in patients2.

Key clinical data from the TRAILBLAZER-ALZ 2 study highlighted the efficacy of donanemab in slowing cognitive and functional decline in patients with early-stage Alzheimer’s disease2. The study showed that patients receiving donanemab experienced a 35% reduction in disease progression rate compared to placebo2. Additionally, 47% of patients on donanemab showed no meaningful decline in daily living activities at 12 months, compared to 29% on placebo2.

With its approval, donanemab, manufactured by Eli Lilly and Company, offers a much-needed option for early Alzheimer’s patients, reinforcing Singapore’s commitment to advancing neurological care4 and innovation.

As a strategic partner of Lilly, DKSH Singapore is proud to bring this breakthrough treatment to patients. Our dedication to improving patient access to innovative healthcare solutions is in line with our purpose to enriching lives, bringing healthcare for all. As part of this partnership, DKSH is committed to ensuring that patients and healthcare professionals have access to the latest developments in Alzheimer’s treatment.


For more information please contact:

DKSH Singapore Pte Ltd.
Imelda Ho
Manager, Marketing & Communications
+65 8801 2945

imelda.ho@dksh.com

 

References 

  1. https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---march-2025
  2. Lormalzi (donanemab) Singapore Prescribing Information. Last updated: 24 Feb 2025
  3. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
  4. http://www.nni.com.sg/news/patient-care/22-increase-in-singaporeans-afflicted-with-neurological-conditions

Contact Us

Looking for a trusted partner?

Contact us to explore how DKSH can help you achieve your goals.